Sign In
Buy CYTK
$82.24
-2.63 (-3.10%)
At Close: Jul 13, 2026
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
03:11pm, Friday, 10'th Jul 2026
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?
07:40am, Tuesday, 07'th Jul 2026
IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
07:30am, Tuesday, 07'th Jul 2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
02:40pm, Friday, 26'th Jun 2026
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
08:15am, Thursday, 25'th Jun 2026
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical asse
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Wednesday, 17'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,7
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
11:56am, Wednesday, 17'th Jun 2026
CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:58am, Tuesday, 09'th Jun 2026
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
07:30am, Monday, 08'th Jun 2026
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytoki
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
12:36pm, Thursday, 04'th Jun 2026
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
07:30am, Monday, 01'st Jun 2026
European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first comme
Cytokinetics to Participate in June Investor Conferences
04:00pm, Wednesday, 27'th May 2026
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following in
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript
03:47pm, Wednesday, 27'th May 2026
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
04:04pm, Friday, 22'nd May 2026
Cytokinetics NASDAQ: CYTK executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug's label, REMS pro
Cytokinetics to Hold Annual Meeting of Stockholders
04:00pm, Wednesday, 20'th May 2026
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026
